Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.
Saved in:
| Title: | Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. |
|---|---|
| Authors: | Urman A; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Ding Y; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Durham J; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Cancer Convergence Institute at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Pancreatic Cancer Precision Medicine Center of Excellence Program at Johns Hopkins University School of Medicine, Baltimore, MD, United States., Wang H; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Cancer Convergence Institute at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Pancreatic Cancer Precision Medicine Center of Excellence Program at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Qi H; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, Baltimore, MD, United States., Narang A; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Pancreatic Cancer Precision Medicine Center of Excellence Program at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Burkhart R; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Cancer Convergence Institute at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Pancreatic Cancer Precision Medicine Center of Excellence Program at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States., He J; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Cancer Convergence Institute at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Le D; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Laheru D; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Thompson E; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Cancer Convergence Institute at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Jaffee E; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Cancer Convergence Institute at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Purtell K; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Waisome-Stephens C; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Liu M; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States., Zheng L; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Cancer Convergence Institute at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Pancreatic Cancer Precision Medicine Center of Excellence Program at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; Mays Cancer Center at the University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, TX, United States., De Jesus-Acosta A; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Cancer Convergence Institute at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Pancreatic Cancer Precision Medicine Center of Excellence Program at Johns Hopkins University School of Medicine, Baltimore, MD, United States.; The Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Mar 09; Vol. 17, pp. 1715761. Date of Electronic Publication: 2026 Mar 09 (Print Publication: 2026). |
| Publication Type: | Clinical Trial; Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1715761 |
